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Abstract 
Malignant pleural effusions (MPE) are a common pathology, treated by respiratory physicians and 
thoracic surgeon alike.  In recent years, several well-designed, randomised clinical trials have been 
published that have changed the landscape of MPE management.  The European Respiratory Society 
(ERS) and the European Association for Cardio-Thoracic Surgery (EACTS) established a multi-disciplinary 
collaboration of clinicians with expertise in the management of MPE with the aim of producing a 
comprehensive review of the scientific literature. 
 
Six areas of interest were identified, including the optimum management of symptomatic MPE, 
management of trapped lung in MPE, management of loculated MPE, prognostic factors in MPE, 
whether there is a role for oncological therapies prior to intervention for MPE, and whether a 
histological diagnosis is always required in MPE.  
 
The literature revealed that talc pleurodesis and indwelling pleural catheters are effective at managing 
the symptoms of MPE.  There was limited evidence regarding the management of trapped lung or 
loculated MPE.  The LENT score was identified as a validated tool for predicting survival in MPE, with 
Brims’ prognostic score demonstrating utility in mesothelioma prognostication.  There was no evidence 
to support the use of oncological therapies as an alternative to MPE drainage, and the literature 
supported the use of tissue biopsy as the gold standard for diagnosis and treatment planning.  
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Introduction 
Malignant pleural effusions (MPE) are common, affecting up to 15% of all patients with cancer.(1)  The 
incidence of MPE is likely to rise as global cancer incidence increases and overall survival improves.  The 
majority of patients with MPE are symptomatic, with breathlessness the most common symptom.(2)  
The presence of MPE usually represents advanced or metastatic disease, and consequently survival is 
poor, ranging from a median of 3 months to 12 months depending on underlying patient and tumour 
factors.(2)  Consequently the focus of treatment is inevitably palliative, and aimed at relieving 
symptoms. 
 
Existing guidelines regarding the management of MPE were published over 7 years ago.(2)  A number of 
high quality trials have been published subsequently, many of which have changed practice.(3-5)  
Additionally, as increasing numbers of pleural interventions are being undertaken and experience with 
different management approaches has grown, new hurdles and issues have become apparent.  This 
statement was written to summarise the evidence with regard to management of MPE in general, and in 
relation to specific questions that may be encountered by clinicians who manage MPE. 
 
 
Methods 
The Taskforce was assembled at the European Respiratory Society (ERS) Annual Congress in London 
2016 with the goal of producing an expert statement on the management of MPE.  The Taskforce was 
created based on the recommendations of the ERS Scientific Committee and the European Association 
for Cardio-Thoracic Surgery (EACTS) Guidelines Committee and included 9 Respiratory Physicians and 5 
Thoracic Surgeons from 9 different European countries (see Appendix A).  The aim of the Taskforce was 
to develop a statement that represented a comprehensive, expert scientific review of the literature, 
identified by systematic searches with conclusions supported by accompanying references.  
 
Topics to be covered by the Statement were decided at the initial meeting of the Taskforce.  Six clinical 
questions were chosen to be covered by the statement. They included the optimum management of 
MPEs, the management of trapped lung and loculated MPE, factors predicting prognosis, whether 
oncological therapy should precede definitive fluid management in treatment-sensitive tumours and 
whether histological diagnosis is always required.  Certain topics had been covered in previous 
guidelines and statements (i.e. questions 1, 3 and 4), and the intention of the Taskforce was to present 
an updated summary of the literature, whilst other topics had not been specifically reviewed before (i.e. 
questions 2, 5 and 6).  Each question, except the question on prognosis, were structured using the PICO 
(Patients, Intervention, Comparison and Outcomes) format.  The PICO criteria for each question are 
presented in Appendix B. 
 
The literature search was undertaken in January 2017 by an Information Scientist at the University of 
York, with guidance from a Taskforce member (ACB).  Three medical databases (Medline/PUBMED 
(National Library of Medicine, USA), EMBASE (Elsevier, the Netherlands) and Cochrane Library (UK)) 
were searched using a combination of MeSH headings and keywords appropriate to the clinical 
question.  Search results were limited to papers in English, relating to adult patients.  The full search 
strategy for each clinical question is shown in Appendix C.  Once the search had been run, further 
potentially eligible articles were identified by snowballing, including reviewing the reference lists of 
identified papers. The search was repeated in January 2018 to identify recently published papers. 
 
Abstracts were screened for inclusion by two taskforce members (ACB and NAM).  Articles were 
included or excluded based on pre-specified eligibility criteria for each clinical question (see Appendix 
D).  Each reviewer screened abstracts independently before results were compared.  Any disagreements 
were resolved by discussion, with involvement from the Taskforce Chairs if necessary. 
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Six sub-groups were formed, with each comprising a combination of physicians and surgeons with a 
range of expertise.  Each sub-group reviewed the full-text articles of the reference material and further 
excluded any articles that did not match the eligibility criteria.  The PRISMA diagram for each clinical 
question is shown in Appendix E. 
Sub-groups prepared drafts summarising the relevant literature for their clinical question.  These drafts 
were reviewed by the Taskforce at a meeting during the 2017 ERS congress in Milan.  Comments and 
suggestions were made, following which sub-groups revised their drafts and submitted to the writing 
committee (ACB & NAM).  The writing committee collated the drafts into a complete statement that was 
circulated to all Taskforce members.  Feedback was incorporated into a revised second draft that was 
disseminated to the Taskforce.  Further revisions were discussed at a teleconference in November 2017, 
leading to production of the final draft.  This was reviewed and approved by all members, hence the 
final document represents a consensus statement of the entire Taskforce. 
 
The statement describes current practice regarding the management of MPEs, and summarises the 
evidence as it currently stands.  The statement does not make recommendations for clinical practice.  It 
has been endorsed by the ERS Scientific Committee and the EACTS Guideline Committee and peer-
reviewed by expert reviewers on behalf of the European Respiratory Journal (ERJ) and the European 
Journal of Cardio-Thoracic Surgery (EJCTC). 
 
 
Question 1 - What is the best definitive treatment for patients with 
symptomatic MPE? 
 
MPE are usually associated with significant symptoms.  Since the majority of patients with MPE will 
experience fluid re-accumulation after therapeutic aspiration, a definitive pleural intervention is 
recommended.(2)  For the purposes of this document, ‘definitive’ is regarded as a procedure intended 
to provide long-term relief from pleural effusion symptoms.  Serial thoracentesis is not considered 
definitive and is therefore not included.  
 
The literature covers many definitive pleural interventions for MPE, including pleurodesis using a 
chemical agent (e.g. tetracycline, doxycycline and bleomycin), talc pleurodesis via thoracoscopy 
(poudrage) or chest tube (slurry), mechanical pleurodesis at surgery, pleurectomy and insertion of 
indwelling pleural catheters (IPC). This document will review the available evidence for the more 
common interventions.   
 
Chemical pleurodesis 
Three systematic reviews assessed the efficacy of different pleurodesis agents.  Bucknor et al conducted 
a best evidence review of silver nitrate as pleurodesis agent, in which 42 papers were identified and 8 
included.(6)  Half of these papers related to animal studies or non-malignant populations, but for the 
four studies undertaken in MPE, silver nitrate pleurodesis rates of 89-96% were reported.  This 
compared favourably with pleurodesis rates of 84% with talc slurry in the only randomised trial included 
in the review.(7)  Further support for silver nitrate was provided by a small case series of 17 patients 
who failed talc pleurodesis, 89% of whom subsequently achieved pleurodesis with silver nitrate.(8) 
 
Tan et al conducted a systematic review and meta-analysis of randomised trials and included 46 studies 
of 2053 patients in total.(9)  Pleural fluid recurred less frequently with talc (poudrage or slurry) 
compared with doxycycline or bleomycin.  In the most recent and most thorough assessment in the 
literature, Clive et al conducted a network meta-analysis of MPE pleurodesis strategies.(1)  Talc 
poudrage was ranked highest in terms of fluid control, with clear benefit compared with bleomycin and 
tetracycline.  Side effects were similar across the agents studied, although large-particle (graded) talc 
was recommended over mixed-particle size to reduce the risk of acute respiratory distress syndrome 
(ARDS).  The authors noted a high or unclear risk of bias in all included studies, as well as high 
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heterogeneity between trials.  There was a lack of patient-reported outcomes and further work is 
required in this area in order to allow clinicians to understand patients’ preferences and formulate 
individualised management plans. 
 
Talc slurry versus talc poudrage  
Three systematic reviews addressed bed-side talc slurry versus thoracoscopic talc poudrage (via surgical 
VATS or medical thoracoscopy). Tan et al demonstrated that poudrage was associated with less 
recurrence than slurry (RR 0.21, 95% CI 0.05-0.93) based on two studies.(9)  In a network meta-analysis, 
talc poudrage was ranked higher than slurry in terms of fluid control, accepting bias in the included 
studies.(1)  Mummadi et al conducted a systematic review and meta-analysis of talc poudrage versus 
slurry.(10) Of 28 studies identified, 4 were included as high quality.  No overall difference in successful 
pleurodesis was found (RR 1.06, 95 % CI 0.99-1.14), but poudrage was associated with a higher risk of 
respiratory complications (RR 1.91, 95% CI= 1.24-2.93). The increased complication rate was driven 
entirely by a single study by Dresler et al, the largest in the literature.  In that trial, 501 patients were 
randomised to talc poudrage or slurry (250 vs 251 patients) using non-graded talc.(11)  The primary 
outcome was radiographic absence of effusion at 30 days, in those that survived and in whom initial 
lung expansion was >90%. There was no difference overall (78% vs 71%), but in a post-hoc, subgroup 
analysis of breast and lung cancer patients, poudrage appeared superior (82% vs 67%). There was an 
excess of adverse events in the talc poudrage group (14% vs 6% for respiratory complications, and 8% vs 
4% for respiratory failure) including 11 deaths.  
 
Yim et al randomised 57 MPE patients with expandable lungs to talc slurry or poudrage, showing no 
difference in any outcome including complications.(12) Similarly, Terra et al randomised 60 patients to 
talc poudrage or slurry, and demonstrated no difference in outcome, although a greater proportion of 
poudrage patients demonstrated complete lung expansion.(13) 
 
Four non-randomised studies compared talc slurry to poudrage. Two studies totalling 277 patients 
demonstrated no difference in pleurodesis outcomes,(14, 15) whereas two others totalling 257 patients 
demonstrated higher pleurodesis success rates, shorter tube duration (9 days vs 6 days) and longer 
effusion free survival with poudrage.(16, 17) 
 
There were 17 case series of >100 patients reporting the utility of talc poudrage in the literature, 
comprising 6347 patients.  Varying doses of talc were used and definitions of pleurodesis success and 
complications differed.  Success rates ranged from 77% to 98%, and complications from 2% to 17.2%, 
including mortality in some studies.(18-34) Important specific results in these studies included no 
incidences of ARDS in 558 patients undergoing talc poudrage with graded talc,(22) lower pleurodesis 
success in patients with pleural pH<7.2,(31) and improved dyspnoea but deteriorating overall quality of 
life post-pleurodesis in MPE.(32)  
 
Chest tube size 
The majority of studies that demonstrated high pleurodesis rates with talc used large bore chest tubes 
(≥24F).  Numerous case series suggest reasonable pleurodesis rates using smaller bore catheters with a 
number of different agents.  
 
Two randomised trials directly addressed chest tube size in pleurodesis. Clementsen et al randomised 
patients to small bore catheter (10F) or large bore tube (24F) for tetracycline pleurodesis.(35) 18 
patients were randomised, and no significant difference in pleurodesis rates was demonstrated. 
Although this was taken to indicate there was no difference in pleurodesis rates according to chest tube 
size in MPE, the study was underpowered for this outcome and was not designed as a non-inferiority 
trial. Rahman et al conducted a 2 x 2 factorial randomised trial assessing opiate versus NSAIDs and small 
(12F) versus large (24F) chest tubes in 320 patients with MPE undergoing talc pleurodesis.(4)  Pain 
comparisons were powered for superiority and pleurodesis for non-inferiority.  Small bore tubes failed 
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to meet the non-inferiority margin of 15%, demonstrating lower pleurodesis success (30% vs 24% 
pleurodesis failure).   
 
Other issues regarding talc pleurodesis 
In the past, it has been assumed that adequate distribution of talc throughout the thoracic cavity was 
required to achieve successful pleurodesis. Mager et al randomised 20 patients to either rotation or bed 
rest in the supine position following administration of radio-labelled talc.(36) No difference in 
distribution was found between the two arms, and thus rotation does not increase the likelihood of 
pleurodesis success.  
 
Pleurodesis is recognised to be a highly painful procedure in some patients, and most physicians use 
opiate analgesia for the procedure. Although non-steroidal anti-inflammatory drugs are effective 
analgesics for acute pain, they have historically been avoided during pleurodesis due to fears that their 
anti-inflammatory effect may reduce pleurodesis success. Rahman et al randomised 320 patients to high 
dose ibuprofen (800mg tds) or opiate during pleurodesis for MPE and demonstrated no significant 
difference in pleurodesis success or pain using a non-inferiority design.(4) These results suggest non-
steroidals need not be avoided in patients undergoing pleurodesis for MPE. 
 
Small-particle (or ungraded) talc is thought to be associated with significantly more side effects than 
large-particle (graded) talc, including ARDS and respiratory failure.(11, 22)  Small-particle talc was 
associated with higher inflammatory cytokine responses in one small, non-randomised, comparative 
study.(37) Interestingly higher inflammatory responses were seen in patients with successful pleurodesis 
following talc poudrage compared with non-successful pleurodesis in a case series.(38) Similarly, higher 
fibrinolytic activity in pleural fluid has been associated with pleurodesis failure.(39)   
 
Whilst pleurodesis aims to palliate symptoms rather than extend survival, one retrospective, non-
randomised study found talc poudrage pleurodesis was associated with longer survival compared with 
repeated thoracentesis.(40)  However, the authors conflated correlation with causality, and ignored 
potential confounding by indication in the two treatment arms.  Another series of 91 patients explored 
factors associated with poor survival after talc poudrage.(41) Poor performance status and prior use of 
chemo/radiotherapy were adverse prognostic factors, and these clinical parameters may be helpful in 
triaging patients to treatments.   
 
Surgical options 
Surgical options for MPE (aside from VATS talc poudrage which is covered in the section above) include 
pleurectomy and abrasion pleurodesis.  Several cases series suggest partial and total pleurectomy are 
effective treatments for MPE.(42-44) 
 
Four randomised trials have compared surgical techniques with “medical” pleurodesis.  Crnjac et al 
randomised breast cancer MPE patients to thoracoscopic abrasion or bedside talc slurry (5g) and 
analysed radiological outcomes stratified by pleural pH levels.(45)  Pleurodesis success rates were not 
significantly different in effusions with pH>7.3 and pH<7.3 (92% vs 91%). Hospital stay was shorter in the 
surgical group (5.5 days vs 7.5 days, p<0.05), and complication rate and mortality also favoured abrasion 
(16% versus 26% and 0% versus 9.5% respectively).  A smaller randomised trial compared the same 
interventions, using surrogate inflammatory outcomes.  Surgical pleurodesis was associated with a 
greater rise in inflammatory cytokines (although non-significant) and better patient-reported 
outcomes.(46)  
 
Gu et al randomised 53 non-small cell lung cancer (NSCLC) MPE patients to video-assisted thoracoscopic 
surgery (VATS) pleurectomy or chest tube drainage, although it is unclear whether a pleurodesis agent 
was given in the chest drain arm.(47) A significant improvement favouring VATS was seen in MPE 
response rates (92.3% vs 59.3%, p<0.05) and Karnofsky performance status (mean 33.5 ± 11.3 and 24.07 
± 10.5, p<0.05), but no differences in overall survival. 
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In the largest randomised trial of its type, Rintoul et al compared fluid control rates in 196 mesothelioma 
patients randomised to VATS pleurectomy or talc pleurodesis using poudrage or slurry.(5) There was no 
significant difference in pleurodesis and VATS was associated with higher expense and increased 
adverse events.  
 
A non-randomised comparison of talc pleurodesis, abrasion and pleurectomy for MPE demonstrated 
longer hospital stays and worse mortality and morbidity following surgery.(48)  Similarly, in another 
study, pleurodesis rates were lower in patients who underwent local anaesthetic thoracoscopy 
compared with VATS, but post-operative drainage, mortality, morbidity and costs were also lower in the 
medical thoracoscopy group.(49) Greater improvements in early physical health, global health and 
dyspnoea were seen with medical thoracoscopy, although this group comprised historic controls and 
were therefore at risk of selection bias. 
 
Indwelling Pleural Catheters 
Indwelling pleural catheters (IPCs) are an alternative to pleurodesis that offer long-term symptom 
control via regular home drainage of fluid.  Multiple case series, totalling 1533 patients, have reported 
their utility in MPE management, specifically in terms of improving breathlessness and other symptoms, 
and quality of life.(50-55) Systematic review of 19 case series, totalling 1370 patients treated with IPC, 
reported symptomatic improvement in 96%, with removal due to complications required in 8.5%.(56)   
 
There are 4 randomised controlled trials comparing IPCs with chemical pleurodesis.(3, 57-59) Putnam et 
al randomised 144 MPE patients to IPC or doxycycline pleurodesis in a 2:1 ratio, demonstrating 
comparable improvement in symptoms in both groups.(57)  However, the IPC group spent less time in 
hospital (1 day vs 6.5 days), and had 46% pleurodesis rate at 27 days.   
 
In the TIME2 trial, Davies et al randomised patients to IPC or inpatient talc slurry pleurodesis via a 12F 
intercostal drain, with a primary outcome measure of patient-reported breathlessness over 6 weeks.(3)    
No significant difference in dyspnoea scores was found between the groups, with a small difference in 
breathlessness favouring IPC at 6 months.  IPCs were associated with reduced time in hospital (0 vs 4 
days) and requirement for further procedures (6% vs 22%), but also with increased adverse events (OR 
4.70, 95% CI 1.75-12.60, p=0.002).  
 
More recently, the AMPLE study randomised 146 patients with MPE to undergo IPC insertion or talc 
slurry pleurodesis via a chest drain.(58)  Patients who received an IPC had shorter hospital stays (10 vs 
12 days, p=0.03) and required fewer subsequent pleural interventions (3 vs 16, p=0.001) than the 
pleurodesis group.  Both arms reported sustained improvements in breathlessness and quality of life 
scores, with no difference between the two arms.  Complication rates were higher in the IPC group (30% 
vs 18%), but there was only one serious adverse event compared with 3 in the chest tube arm.  
 
Demmy et al randomised 57 patients to IPC placement with daily drainage or bedside talc pleurodesis, 
with a composite primary outcome of “success” based on reliable drainage, pleurodesis and 30 day 
survival.(59)  Recruitment target was not met, and a secondary endpoint of survival with effusion 
control was added retrospectively.  However, IPCs were more successful for the primary outcome (62% 
versus 46%, p=0.064) and secondary outcome (82% vs. 52%, p=0.024).  However, the results of this 
study should be interpreted with caution given the failure to recruit the target sample size, the potential 
bias introduced by adding outcomes post-hoc, and the limited clinically applicability of the primary 
outcome. 
 
Three non-randomised studies compared IPCs with poudrage,(60) talc slurry,(61) and VATS 
pleurodesis/decortication.(62) These studies reported reduced hospital stay and fewer repeat 
procedures for IPCs compared with slurry or poudrage,(60, 61) but reduced survival compared with 
decortication.(62) However, all suffer from potential selection bias. One study assessed patient reported 
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outcome measures in MPE interventions including patients having IPC, talc slurry pleurodesis and 
surgical VATS.(63) All patients demonstrated improved functional assessment and breathlessness 
scores, with no statistically significant difference between treatment groups.  
 
Regarding IPC drainage regimens, the multi-centre, randomised ASAP study revealed that daily IPC 
drainage was more likely to result in auto-pleurodesis, either complete or partial, within 12 weeks 
compared with alternate day drainage (47% vs 24% pleurodesis rate, p=0.003).(64)  Adverse event rates 
(and specifically infection rates) were similar in the two arms and although almost 30% of the 149 
patients randomised died before the 12 week primary end-point, deaths were evenly distributed 
between the two treatment regimens.  Importantly, patients with trapped lung were excluded from the 
study - a pertinent consideration when applying this result to clinical care, as aggressive drainage is likely 
to cause significant pain in this population. Careful evaluation of individual patients is therefore required 
before a daily drainage approach is followed.   
 
Combined Procedures 
Given the increasing evidence supporting IPCs, there is increasing interest in combining their use with 
other pleurodesis procedures.  Three case series totalling 148 patients reported the use of IPCs during 
VATS,(65) and combined with talc poudrage pleurodesis.(66, 67) The combination of poudrage and IPC 
was associated with short hospital stays (1 to 3 days) and removal of catheters after successful 
pleurodesis within around 7 days.  A single non-randomised study used propensity matching to compare 
VATs poudrage with IPC placement at VATS in 60 patients.(68) The IPC group had shorter hospital stays 
and lower morbidity.  
 
Therefore, there is a lack of high quality randomised evidence for the use of combined procedures in 
MPE, but this is a potential treatment direction for the future.  
 
In summary 
Talc is the most effective agent for chemical pleurodesis in MPE, and graded particle talc appears safe. 
The data suggests that thoracoscopic talc poudrage (via surgical VATS or medical thoracoscopy) may be 
slightly more effective than slurry for MPE pleurodesis, and an on-going randomised trial in the UK is 
aiming to answer this question.(69) Surgical pleurodesis procedures are no more effective than talc, 
especially in mesothelioma where RCT evidence shows that VATS pleurectomy is associated with more 
complications and longer hospital stays, but no additional benefit in terms of pleurodesis success.(70) 
 
Large bore tubes (i.e 24F) are associated with higher pleurodesis success rates in talc pleurodesis than 
smaller drains (i.e. 12F), with non-steroidals an effective analgesia option that do not lower pleurodesis 
rates.  IPCs appear to be as effective at relieving MPE symptoms as talc pleurodesis and are associated 
with reduced time in hospital, although adverse event rates appear to be higher than for talc. 
 
 
Question 2 - What is the optimal management for MPE with trapped lung?  
 
Trapped lung describes the situation where the lung is unable to fully expand to fill the hemithorax, 
rendering the parietal and visceral pleura either partly or completely unopposed.  Trapped lung can 
occur as a result of pleural thickening causing encasement of the lung, proximal endobronchial 
obstruction causing distal lung collapse or chronic atelectasis.  Some authors differentiate between 
“lung entrapment”, in which an active pleural process, such as malignancy, causes a visceral pleural peel 
to form, thus preventing lung expansion, and “trapped lung”, in which the fibrous peel has arisen as a 
consequence of remote inflammation in the pleural space that is no longer active.(71, 72)  However for 
the purpose of this document, the term “trapped lung” will be used to cover both clinical entities. 
 
Whether trapped lung can be predicted is an issue beyond the scope of this document. Pleural 
manometry, M-mode ultrasonography and patients’ symptoms during aspiration have all been proposed 
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as methods of predicting trapped lung.(71, 73-78)  However, as yet none have been proven 
prospectively and further evidence is required before they can be adopted into routine clinical practice. 
 
Regarding the management of trapped lung in MPE, there is little high-quality evidence.  The literature is 
complicated by certain issues, including different definitions of the disease and the potential for 
variation in the degree of lung entrapment between individual patients and studies.  Additionally several 
studies include patients with trapped lung, loculated effusions or previous failed pleurodesis, but do not 
clearly differentiate between patient groups when reporting outcomes.  There are no randomised 
controlled trials investigating trapped lung specifically, and consequently the evidence must be 
interpreted with awareness of the risk of selection bias (in non-comparative studies) and confounding 
by indication (in non-randomised comparative studies).  Furthermore it is highly likely that institutional 
preference and expertise may determine the choice of intervention for trapped lung, introducing 
additional bias. 
 
A single systematic review focussing on the optimal approach to MPE concluded that IPCs are indicated 
in trapped lung.(79)  This conclusion was based on 2 studies out of 14 included in the review.  The first, 
by Pien et al, was a retrospective review of 11 patients with trapped lung, who underwent IPC insertion 
and home drainage.(80)  All but one patient described symptomatic benefit, and 12/13 catheters placed 
remained in situ until the patient died.  Serious adverse events, namely empyema, IPC blockage and 
catheter fracture, occurred in 3 patients.   
 
Additional information regarding IPC in trapped lung is available from Demmy et al’s randomised trial of 
talc pleurodesis versus IPCs in MPE.(59)  The sub-group of 9 patients with trapped lung had higher 
effusion control rates at 30 days in the IPC arm compared with talc pleurodesis, alongside better 
dyspnoea-free exercise scores (7.8 versus 4.5, p=0.02).  
 
A non-randomised comparative study compared the use of poudrage pleurodesis at VATS to IPCs, with 
intervention chosen according to whether trapped lung was present, suggesting successful treatment in 
trapped lung with IPCs.(81) 
 
There are several observational studies reporting the value of IPC in MPE trapped lung, the results of 
which are summarised in Table 1.  It is worth noting that symptomatic outcomes were inconsistently 
defined across these studies, and whilst some studies reported the number of patients who experienced 
symptomatic relief, others subjectively graded the size of the response in individuals.  Nonetheless, IPCs 
appear effective in trapped lung, with symptomatic improvement reported in over 94% of patients in 
five studies totalling 133 patients,(51, 80, 82-84) although a single study of 48 patients reported lower 
symptom relief rates of 48%.(85)  Three of these studies included patients who had undergone VATS 
and been diagnosed with trapped lung intra-operatively, hence received an IPC at the end of the 
procedure.(55, 82, 85)  In these studies, it is impossible to determine which procedure was responsible 
for which outcomes, both in terms of symptomatic benefit and adverse events, which were numerous.  
Length of stay was consistently shorter for trapped lung patients treated with IPCs than for comparator 
groups (usually comprising patients with non-trapped lung undergoing VATS talc poudrage).(81, 82)  
 
Other approaches to managing malignant trapped lung include surgical decortication and intra-pleural 
fibrinolytics.  Pleuroperitoneal (PP) shunts have been used historically in trapped lung, however the 
supporting evidence is of poor quality, complications rates are high and they are not currently used in 
routine clinical practice.(34, 86, 87)  From a surgical perspective, Yim et al reported “good outcomes” in 
7 patients with trapped lung who underwent VATS decortication.(88)  A randomised controlled trial is 
underway in the UK assessing the role of surgical pleurectomy/ decortication versus IPC in patients with 
mesothelioma and trapped lung (Meso-TRAP). 
 
Hsu et al investigated the use of 100,000 IU urokinase via IPCs in surgically inoperable patients with 
trapped lung or loculated effusions.(89)  3 out of 12 trapped lung patients demonstrated “excellent” 
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radiographic improvement following treatment, which persisted until death in 2/3.  No adverse events 
were reported.  However, the relevance of radiographic resolution, specifically its inconsistent 
relationship with symptoms make this finding difficult to interpret in a clinical context. 
 
In summary 
There is a lack of good quality published evidence but IPCs appear to be an effective option in the 
management of MPE trapped lung.  Dedicated prospective trials are needed to fully evaluate the utility 
of IPCs in trapped lung, and also to evaluate surgical interventions and the role of fibrinolytics. 
 
 
Question 3 – How should septated and loculated MPE be managed? 
  
Loculated MPE are defined as MPE with multiple loci, i.e. there is more than one fluid collection, or the 
effusion is divided into multiple separate pockets of fluid.  This is different to septated effusions, where 
fibrinous strands have formed within an effusion, usually as a result of excessive fibrin formation due to 
inflammatory-mediated changes in procoagulant and fibrinolytic activity.(90)  Septated effusions may 
become loculated over time, but the presence of septations in MPE does not necessarily prevent free 
flow of fluid within an effusion.   In contrast, loculation may prevent complete drainage of the pleural 
space and limit lung re-expansion, thus potentially contraindicating pleurodesis or resulting in 
insufficient symptomatic relief in patients with IPCs.  
 
Septations are common in MPE. One retrospective analysis of 540 consecutive patients who underwent 
medical thoracoscopy for MPE found that 332 (60%) had some degree of adhesion (i.e. septation), which 
obstructed 2/3 or more of the thoracoscopic view in 84 (15%).(91) The extent of pleural adhesions 
correlated with a greater pleural tumour burden and shorter median survival.(91)   Transthoracic 
ultrasonography (TUS) outperforms computed tomography (CT) in the identification of septations. In a 
prospective study of 64 patients undergoing VATS, pre-operative CT had 71% sensitivity and 72% 
specificity for detecting septations.(92) In contrast, two series of 142 and 117 patients reported 
sensitivities of 81% and 88% respectively, alongside 96% and 83% specificity for ultrasound identification 
of septations prior to thoracic surgery.(93, 94) Another small observational study further supported the 
use of TUS over CT as an effective method for identifying thick pleural septations prior to thoracoscopy 
(sensitivities 100% and 12.5% respectively).(95) 
 
TUS has a role in loculated effusions, and has been shown to reduce complications and increase yield 
when used to guide interventions in loculated collections.(96, 97)  However, the utility of TUS is limited 
in the presence of mediastinal loculations or loculations involving the fissures, as the overlying lung 
prevents imaging of the fluid beneath it.  In these situations, computed tomography (CT) is of greater 
value, with a high sensitivity for identifying loculations.(97, 98) 
 
Septations can be broken up under direct vision at thoracoscopy (medical or surgical), whilst thoracic 
surgery is usually required to access multiple loculations, especially those positioned on the 
mediastinum.  Multiple drains have been used to drain loculated effusions in the setting of pleural 
infection,(99, 100) however in patients with MPE multiple procedures are not ideal.  Additionally, if the 
underlying lung is non-expandable, pleurodesis will be ineffective and therefore this approach will not 
result in definitive fluid control.   
 
Intra-pleural fibrinolytic agents have been shown to improve fluid drainage in loculated pleural 
infection,(101) and uncontrolled small case series have reported their use in symptomatic loculated MPE 
with incomplete initial drainage.(102-109) Intra-pleural fibrinolytics increased fluid drainage in all cases, 
and improved symptoms and radiological appearances in 60%,(109) 86%,(108) and, in most studies, 
100% of patients.(102-107) Different drugs, including streptokinase,(102-106, 109) urokinase,(108) and 
tissue plasminogen activator (t-PA),(107, 109) were employed at varying dosages.  
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Four controlled studies, three of which were randomized, investigated the role of intra-pleural 
fibrinolysis for the treatment of loculated MPE.(89, 110-112) The first, which used a historical control 
group, prospectively evaluated 36 patients with symptomatic loculated MPE after drainage with an 8F 
catheter who were unsuitable for surgery.(89) The administration of intra-pleural urokinase (100,000 IU 
daily for 3 days) resulted in a reduction in radiological effusion size of greater than two-thirds in 26 
(72.2%) patients.  All 26 subsequently received minocycline pleurodesis, with life-long fluid control in 21 
(80.8%). Radiological lung expansion was significantly greater than in 40 retrospectively analysed 
historical controls with loculated MPE who did not receive fibrinolytics.  
 
The second study randomized 47 patients with symptomatic MPE to receive intra-pleural streptokinase 
(250,000 IU twice daily for 3 doses) or pleural drainage only.(110)  No information was provided 
regarding the existence of pleural adhesions. 96% of patients in the fibrinolytic group achieved 
radiological lung expansion and were subsequently able to receive talc slurry, compared with 75% in 
controls (p=0.035). However, pleurodesis success at 1 month was similar in both groups (74% vs 56%, 
p=0.28).  
 
The third study randomly allocated 40 patients with loculated MPE on CT to receive intra-pleural 
streptokinase (4 separate doses of 250,000 U) or placebo (saline) administered through a 20F tube, after 
which talc slurry pleurodesis was performed.(111) The fibrinolytic group had higher daily drainage 
volumes at all time points (p<0.001), with a greater proportion of patients showing CT improvements of 
greater than 40% (85% vs 35%, p=0.001).  Fibrinolytic therapy was also associated with reduced 
requirements for supplementary oxygen (10% vs 45%) and lower rates of pleurodesis failure at 1 month 
(11% vs 45%), although only the first result reached statistical significance.  
 
Finally, in the TIME3 trial, 71 patients with non-draining MPE due to fibrinous adhesions received either 
urokinase (100,000 U three doses over 36 hours) or placebo, followed by talc slurry pleurodesis after 24 
hours.(112)  There was no difference in dyspnoea scores on visual analogue scale over the first month or 
pleurodesis failure rates at 1 year in the fibrinolysis group compared with placebo. However, urokinase 
performed better than placebo for secondary outcome measures, including a 18% greater reduction in 
pleural opacity on chest radiograph 2 days post-randomization, shorter length of hospital stay (6.2 vs 8.7 
days) and improved survival (48 vs 69 days; all p<0.05).  Notably, 48% of the study population died 
within 1 month of randomization, highlighting the extremely poor prognosis of patients with this 
problem. 
 
The use of fibrinolytics in patients with IPCs and loculated MPE has been studied in one multi-centre 
retrospective review.(113)  66 patients (64 with an MPE) who developed symptomatic loculations with 
IPCs in situ were treated with intra-pleural fibrinolytics. Most patients received a single dose (range 1-6) 
of either t-PA (n=52), urokinase (n=12) or streptokinase (n=2). Following therapy, the volume of pleural 
fluid drained increased in 93.3% and dyspnoea improved in 83%. The area of pleural opacity on chest 
radiograph decreased from 52% to 31% of the hemithorax in 13 evaluable patients. However, 
symptomatic loculations recurred in 27 (41%) patients and of 10 patients who received repeated 
fibrinolytic therapy only 1 had a sustained improvement in drainage and symptoms.  
 
In summary 
Intra-pleural fibrinolytics increase the volume of fluid drainage and improve the radiological appearance 
in loculated MPE. However, they have no effect on clinical outcomes, such as dyspnoea or pleurodesis 
success.  Alternatives, however, are limited for patients with loculated MPE who are not suitable for 
surgery. 
 
 
Question 4 - What factors predict prognosis in MPE? 
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MPE management depends on prognosis.  Patients with long survival require definitive interventions, 
whilst the aim for people with short life expectancy should be to maximise time at home.(2)   
 
Certain factors, i.e. tumour type, stage and performance status (PS), are accepted prognostic factors in 
malignancy, including MPE.  In MPE, lung cancer carries the worst prognosis, whilst longer survival is 
seen in gynaecological tumours, predominantly due to the underlying tumour’s sensitivity to 
treatment.(2, 114-120)  Staging systems exist for each tumour that formally describe disease extent and 
prognosis.(121)  Usually MPE signifies metastatic disease, higher stage and shorter survival, although 
mesothelioma is an exception to this rule.(121, 122)  Finally, PS is a global evaluation of function that 
predicts outcome in cancer, including as a tool to assess patients’ suitability for oncological 
treatment.(116, 117, 120, 123-128)    
 
Prognosticating in MPE 
Specific MPE-related prognostic factors include effusion size. Massive MPE, defined as fluid occupying 
the entire hemi-thorax, was associated with significantly worse survival in one large, prospective 
study.(129)  This finding was replicated in a subsequent retrospective study, although the definition of 
massive effusion differed.(118)   
 
Pleural fluid pH may also predict survival - an early study demonstrated worse prognosis in patients with 
pleural fluid pH<7.2.(130)  However, whilst several subsequent studies replicated the original finding, 
albeit using lower pH cut-offs,(31, 118, 128) others found no relationship between pH and survival.(41, 
125) Patient-level data from these studies was pooled in a meta-analysis that confirmed pH≤7.28 was 
associated with shorter survival.(115)  However, pH could not reliably predict 3 month survival and was 
therefore insufficiently accurate for clinical use.  Pleural fluid glucose, which is closely related to pH, was 
similarly non-predictive.(31, 41, 118, 125, 128)  
 
Other potentially prognostic pleural fluid variables include LDH, which correlated with survival in 
multiple observational series.(118, 128, 130) Haemorrhagic fluid was also associated with reduced 
survival times in patients with lung cancer,(118) and was a poor prognostic factor in patients with MPE 
undergoing thoracoscopy.(131)  Positive pleural fluid cytology does not predict survival,(117, 131) 
although detection of specific receptors or mutations e.g. EGFR, in fluid can have treatment and 
prognostic implications.(132, 133)  Interestingly, high serum levels of Vascular Endothelial Growth 
Factor (VEGF) did not predict response to bevacizumab (a VEGF antagonist) in mesothelioma.(134)  
However, high serum and pleural fluid VEGF levels are associated with worse outcomes in MPE,(135, 
136) as are the downstream effects of inflammation, angiogenesis and tumour necrosis.(137, 138) 
 
Inflammation and cancer are closely related, and serum inflammatory markers can predict 
prognosis.(139-142) The Glasgow Prognostic Score (GPS) combines C-reactive protein (CRP) with serum 
albumin and has been validated to predict survival in several tumour types.(143-145)  Another 
inflammation-based prognostic score is the serum neutrophil-lymphocyte ratio (NLR), high values of 
which reflect raised neutrophils, low lymphocytes, or both.   Raised neutrophils are an adverse 
prognostic marker in non-small cell lung cancer, melanoma, renal cell carcinoma and others.(146-149)  
Lymphocytes, however, are fundamental to immune-mediated cancer control and low counts result in 
less effective tumour destruction and worse survival.(150-152)  The NLR combines these two variables 
to provide a simple prognostic value that has been shown to be accurate in many cancers.(41, 144, 153-
159) 
 
Chronic inflammation causes catabolism and cachexia, which has further negative implications in 
MPE.(140-142)  Low albumin has been shown to be an independent prognostic factor, as well as 
predicting outcome as part of the Prognostic Nutritional Index – a validated predictor of survival in 
mesothelioma and other malignancies.(143, 144, 160-162)   
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Many prognostic scoring systems have been suggested for MPE.  However, only one has been externally 
validated.  The LENT score was developed using data from 789 patients across 3 international 
centres.(155)  Baseline factors were analysed for prognostic value and those with the strongest 
predictive ability included in the predictive model (see Figure 1).  Final scores separated patients into 
low, moderate or high risk groups, with median survival of 319, 130 and 44 days respectively.  Validation 
produced similar results, confirming that LENT is an accurate and robust tool for predicting MPE 
prognosis. The simplicity of the score makes it attractive for both clinical practice and research settings.  
  
Prognostication in mesothelioma 
Multiple observational studies have reported prognostic factors in mesothelioma, although many were 
susceptible to selection bias, having been undertaken in selected populations.(163-170)  The 
forthcoming ERS Taskforce Statement on mesothelioma contains information on prognostication, and 
therefore a full summary of the literature is not replicated here.  
 
In brief, certain factors are consistently associated with survival in mesothelioma, namely gender, age, 
epithelioid differentiation, PS, and tumour stage.(116, 156, 163-169, 171-180)  The relationship between 
survival and other factors such as quantification of asbestos exposure and presenting symptoms are less 
clear.(162, 164, 167, 172, 181-183)  Multiple inflammatory markers correlate with survival, including 
white cell count,(120, 144, 156, 161, 165, 167-169) platelet count,(156, 163, 165, 168, 169, 171, 176) 
CRP,(156, 163, 165, 168, 169, 171, 176) platelet to lymphocyte ratio,(144) and lymphocyte to monocyte 
ratio.(161)   Local inflammation also affects prognosis, with lymphocytic infiltration of tumours and 
tumour stroma associated with longer survival following surgery.(152, 157)  Much work has been done 
investigating potential prognostic biomarkers, including mesothelin, osteopontin and megakaryocyte 
potentiating factor (MPF).  However, heterogeneity in thresholds and sampling intervals mean that 
these tests are not yet sufficiently reliable to be employed in standard care.(158, 184-186) 
 
Numerous unvalidated prognostic indices exist in the literature,(137, 156, 169, 170, 181, 182, 187-190) 
but only 3 have been externally validated.(168, 182, 191)  Of the validated scores, two used pooled data 
from clinical trials and consequently have limited generalisability to the overall mesothelioma 
population.(168, 182)  In contrast, Brims et al used an unselected cohort of 482 sequential 
mesothelioma patients to develop their prognostic tree, which was then validated in a separate 
consecutive cohort, creating a more representative and clinically useful tool.(191)  The resultant 
decision tree separated patients into one of four prognostic groups, with survival falling from 34 months 
in Group 1 to 17.7, 12.0 and 7.4 months in subsequent groups (see Figure 2).  The model showed 
reasonable accuracy for predicting death at 18 months, with 94.5% sensitivity and 76% positive 
predictive value.  
 
In summary 
Multiple baseline factors predict prognosis, including tumour type, stage, PS and inflammatory markers 
in blood and pleural fluid.  Although multiple prognostic tools have been published, only the LENT score 
has been validated in MPE, and Brims’ decision tree is the most clinically useful in mesothelioma. 
 
 
Question 5 - Should patients with MPE and cancer that is sensitive to 
oncological treatment (e.g. chemotherapy, immunotherapy, targeted therapy) 
receive treatment prior to definitive management of their MPE? If so which 
cancers? 
 
To date, no international guidelines recommend the use of anti-tumour medical treatment, e.g. 
chemotherapy, targeted therapy and/or immunotherapy, before standard palliative procedures for MPE 
management.  Additionally, no randomised controlled trials were identified that compared palliative 
procedures for MPE with anti-tumour treatment.  
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However, observational studies suggest chemotherapy may be an effective first-line treatment in certain 
treatment-sensitive tumour types. For example, a retrospective study in small-cell lung cancer (SCLC) 
demonstrated resolution of MPE following first line chemotherapy in 34 of 62 patients (55%).(192)  In 
contrast, another series of 30 patients with MPE due to SCLC reported increased myelosuppression 
following chemotherapy compared with 30 matched patients without MPE.(193) Whilst association 
should not be mistaken for causality, this observation supports the hypothesis that chemotherapy may 
accumulate in undrained effusions leading to increased toxicity.(192-194) Consequently the authors 
recommend that effusions be drained prior to commencing systemic chemotherapy.   
 
By contrast, in lymphoma, case reports have suggested systemic therapy may be effective treatment for 
MPE,(195, 196), whilst another retrospective study reported control of MPE in 20 patients with T cell 
lymphoblastic lymphoma who were treated with various systemic agents and mediastinal 
radiotherapy.(197)  In NSCLC, several retrospective studies have described the role of systemic 
chemotherapy in patients with MPE, however the significant selection bias affecting these studies 
precludes meaningful clinical interpretation.(198-200)  Finally a single case report describes complete 
resolution of MPE following initiation of chemotherapy in a patient with metastatic ovarian cancer.(201) 
 
Molecular targeted therapy has been investigated in patients with MPE and NSCLC.(202-204)  A case 
report described disappearance of MPE secondary to lung adenocarcinoma following treatment with 
bevacizumab, carboplatin and paclitaxel.(204)  In a single-arm prospective study, 76 patients with MPE 
and epithelial growth factor receptor (EGFR) mutations were treated with oral gefitinib (an EGFR tyrosine 
kinase inhibitor, TKI) until disease progression, toxicity or withdrawal.(202)  MPE were assessed with CT 
scans every three months.  70 patients (92%) had a reduction in MPE of >50% that lasted at least 3 months.  
However, 48 developed subsequent MPE recurrence and 33 went on to receive talc pleurodesis.   Another 
study, retrospective and non-randomised, added bevacizumab to chemotherapy alone or to 
chemotherapy plus EGFR-TKI in 86 patients with MPE due to EGFR-positive NSCLC with acquired EGFR-TKI 
resistance.(203)  PFS was longer in the bevacizumab/EGFR-TKI/chemotherapy group (6.3 vs 4.8 months, 
p=0.048), and longer still in patients with acquired T790M mutations treated with the triple regimen (6.9 
vs 4.6 months, p=0.022).  However there was no difference in overall survival between the treatments.   
Selection bias is likely to have affected the results of both studies, and prospective randomised trials are 
needed to further clarify the role of targeted therapies in MPE with specific mutations. 
 
A number of trials have investigated intra-pleural targeted therapies in MPE.  Two phase I studies explored 
the safety of intravenous and intra-pleural chemotherapy alongside monoclonal antibodies (mAb) in 
MPE.(205, 206)   Safety profiles were variable and numbers were too small to comment on efficacy.  Two 
randomised phase II studies have investigated the anti-VEGF mAb, bevacizumab, intra-pleurally in 
patients with NSCLC and MPE.(207, 208)  In one, a combination of bevacizumab and paclitaxel were 
administered intra-pleurally, leading to reduced pleural effusion size and improved symptoms in 78.6% of 
patients compared with 50% treated with intra-pleural paclitaxel alone.(207)  The 1-year survival rate was 
higher in the bevacizumab arm (45.8% versus 20.8%), whilst adverse events were similar between the 
groups.  The second phase II trial compared intra-pleural cisplatin with or without bevacizumab in 70 
patients with MPE in non-squamous NSCLC.(208) Better MPE response rates (85.7% versus 56.6%) were 
seen with the addition of bevacizumab.  Another, single-arm phase II study used intra-venous 
bevacizumab alongside systemic carboplatin-pemetrexed chemotherapy and demonstrated MPE control 
in 21 out of 23 patients (91.3%).(209)  Again, further research is needed to determine the efficacy of this 
approach. 
 
In summary 
The current literature is limited, consisting mainly of small retrospective series or single-arm prospective 
studies.  Thus no conclusions can be drawn on the value of anti-tumour treatment in MPE management. 
Since there is no strong evidence to suggest any detriment associated with standard interventional 
management of MPE, this is likely to remain the first line of treatment until evidence emerges to support 
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alternative approaches. Further studies are needed, specifically, to confirm the use of intra-pleural 
bevacizumab in NSCLC MPE and EGFR TKI in patients with MPE due to NSCLC with mutated EGFR.  
 
 
Question 6 - In order to determine treatment in MPE, is a histological diagnosis 
always required or is cytology sufficient?  
 
The aim of cytological and histological investigations is twofold – to obtain a diagnosis and to determine 
therapeutic options.  As cancer treatment options expand to include targeted therapies, immunotherapy 
and personalised treatments, the question of which investigation yields the most pathological information 
has become increasingly pertinent.    
 
The diagnostic yield of pleural fluid cytology varies depending on tumour type, tumour load, sample 
quality, expertise of cytologist and availability of specific ancillary tests e.g. gene expression. The mean 
diagnostic sensitivity of pleural fluid cytology for malignancy is between 49% and 91%, with maximal yield 
from two separate samples.(210-220)  Cytology has the highest diagnostic yield for adenocarcinoma, 
compared with mesothelioma, for which sensitivity is generally accepted to be around 30%, but may fall 
as low as 16%.(214-216)  With respect to mesothelioma, cytological diagnosis is particularly challenging 
given that tissue invasion is not always present and histological subtypes can be difficult to 
differentiate.(221) The yield of cytological diagnosis in epithelioid mesothelioma is higher in the presence 
of visceral pleural invasion.(222) 
 
Analysing larger volumes of pleural fluid may improve diagnostic sensitivity in MPE, although there 
appears to be a threshold.  Several studies confirmed that submitting more than 75mL of pleural fluid for 
cytological examination does not improve the yield when using direct smear method.(223-225) However, 
if both direct smear/cytospin and cellblock preparations are utilised, up to 150mL is recommended.(226) 
This combined method has been shown to offer additional value compared to smear slides alone.(227, 
228) 
 
Initial cytological evaluation of pleural fluid involves identifying cells and characterising them as 
benign/reactive or malignant, based on morphological and immunohistochemical parameters. If 
malignant cells are seen, further evaluation is required to determine their origin, i.e. primary pleural 
malignancy versus metastatic disease.  Disease-specific immunochemical markers are summarized in Table 
2.(229-233)   
 
Flow cytometry may be an additional useful adjunct in the differentiation of lymphoma in pleural 
fluid.(234, 235) However, its role in the diagnosis of non-lymphoma MPE has not been fully established, 
with studies demonstrating variable sensitivities of between 50% and 94%.(236-238) Further innovative 
approaches may advance this technique in future.(239) 
 
Where mesothelioma is suspected, specific tests are frequently required due to the complexities 
associated with making this diagnosis.  Sarcomatoid mesothelioma is particularly difficult to diagnose, as 
mesothelial markers are often negative.   Additionally, there are no specific antibodies that differentiate 
between sarcomatoid mesothelioma and other sarcoma-type tumours, although GATA3 has shown early 
promise in one small study.(240)  Loss of BAP1 expression and homozygous deletion of p16 detected at 
fluorescent in-situ hybridisation (FISH) are highly specific indicators for mesothelioma, but negative results 
do not exclude the diagnosis.(241-244)  These tests can be undertaken on both pleural fluid and biopsy 
samples, although sensitivity is reduced if no atypical mesothelial cells are present in effusion 
samples.(242-244)  Consequently, although some laboratories are confident making definitive cytological 
diagnoses,(217, 245) the International Mesothelioma Interest Group recommends that the diagnosis 
should always be based on biopsy.(231)  Evaluation of biopsy tissue can also provide prognostic 
information in mesothelioma, as certain histological features, such as nuclear atypia and mitotic index are 
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correlated with prognosis in epithelioid disease.(246-249)  
 
Mesothelioma aside, the pauci-cellular nature of pleural fluid often results in insufficient cells on which to 
perform the necessary tests to confirm the diagnosis.(250)  Additionally, tissue-specific gene expression 
and receptor status profiling may be required to assess suitability for therapeutic options such as 
molecular therapies, and pleural fluid alone is rarely sufficient for this.  Whilst newer molecular profiling 
technologies such as high-throughput, next-generation and Sanger sequencing have shown promise in 
detecting genetic mutations on MPE cell blocks, they require further investigation before widespread 
adoption into clinical practice.(250-253) Consequently pleural biopsy is usually necessary to provide 
sufficient tissue for analysis.  Thoracoscopic pleural biopsies have a diagnostic sensitivity of over 92% for 
malignancy, and consistently outperform cytological examination, even when cell block preparation is 
performed.(254-256)   
 
Even though pleural biopsy is the gold standard for diagnosing pleural malignancy, false negative results 
can occur.  Observational follow-up studies of patients whose original biopsies showed non-specific 
pleuritis found that up to 15% were subsequently diagnosed with pleural malignancy, most frequently 
mesothelioma.(257-261)  The decision whether to undertake repeat biopsies, possibly via a different 
approach, is usually made based on clinical suspicion and individual patient factors (e.g. suitability for 
surgery).  Whatever pathway is chosen, many clinicians elect to undertake long-term radiological 
monitoring to ensure malignancy is not missed. 
 
Recently, highly sensitive assays have been developed which allow the identification of circulating cell-free 
tumour DNA (ctDNA/cfDNA), tumour RNA especially microRNAs (miRNAs) and circulating tumour cells 
(CTCs) from patients’ blood samples.(262, 263)  These “liquid biopsy” methods have proven useful in lung 
cancer patients in the detection of baseline EGFR mutations,(264, 265) and identification of mutations 
conferring resistance to targeted therapy, e.g. T790M EGFR mutation.(266, 267)  Whilst several of these 
assays have been approved by regulatory authorities for use in clinical care, they are not yet universally 
accessible.  Furthermore, for some tumours, e.g. mesothelioma, no standardised approach has been 
developed and further studies are needed.(268-270) 
 
In summary 
Cytology can provide useful diagnostic, prognostic and therapeutic information, however low sensitivity 
remains an issue especially in mesothelioma.  Pleural biopsy remains the gold standard, although in cases 
where initial biopsies yield inflammation, repeat biopsy or extended follow up is usually required. Newer 
technologies such as liquid biopsy may negate the need for biopsies in future, but further research is 
needed to ascertain their optimal role. 
 
 
Conclusions 
This taskforce statement aimed to review the literature relating to the management of MPE, focussing 
specifically on issues that may be relevant to respiratory physicians, thoracic surgeons and oncologists in 
routine clinical practice.   
 
The highest quality evidence for the optimal treatment of symptomatic MPE suggests that talc 
pleurodesis (via slurry or poudrage) and indwelling pleural catheters are both highly effective, and 
significantly improve symptoms. It is still unclear whether talc poudrage is more effective than talc 
slurry, and while indwelling catheters reduce time in hospital, they are associated with a modest 
increase in adverse events with long term use. 
 
In the context of trapped lung, evidence is lacking with regard to effective treatment options.  IPCs often 
improve symptoms, but prospective randomised trials are required.  Similarly, options are limited in 
loculated MPE with little evidence to suggest that intra-pleural fibrinolysis has any sustained effect on 
patient symptoms and well-being.   
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Regarding prognostication, the LENT score is a simple, validated tool for predicting survival in MPE, 
whilst Brims’ decision tree is most useful in mesothelioma.  At present, there is no robust evidence to 
support the use of oncological therapies as an alternative to mechanical drainage, although further 
research is required.  Currently, although cytological analysis can provide some diagnostic information in 
MPE, tissue biopsy remains the gold standard. 
 
In conclusion, the management of MPE has advanced significantly since the most recent international 
guidelines were published, with several high-quality randomised controlled trials providing robust 
evidence to inform clinical practice.  However, a number of unanswered questions remain, and ongoing 
research is required in order for clinicians to provide optimal care for this patient group. 
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